Developing aerosol vaccines for Mycobacterium tuberculosis

Workshop proceedings. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.

Aerosol Vaccines for Tuberculosis Workshop Summary Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

On April 9, 2014, Aeras and the National Institute of Allergy and Infectious Diseases convened a workshop entitled "Developing Aerosol Vaccines for Mycobacterium tuberculosis" in Bethesda, MD. The purpose of the meeting was to explore the potential for developing aerosol vaccines capable of preventing infection with M. tuberculosis (Mtb), preventing the development of active tuberculosis (TB) among those latently infected with Mtb, or as immunotherapy for persons with active TB. The workshop was organized around four key questions relevant to developing and assessing aerosol TB vaccines: (1) What is the current knowledge about lung immune responses and early pathogenesis resulting after Mtb infection and what are the implications for aerosol TB vaccine strategies? (2) What are the technical issues surrounding aerosol vaccine delivery? (3) What is the current experience in aerosol TB vaccine development? and (4) What are the regulatory implications of developing aerosol vaccines, including those for TB? Lessons learned from the WHO effort to develop an aerosol measles vaccine served as a case example for overall discussions at the meeting. Workshop participants agreed that aerosol delivery represents a potentially important strategy in advancing TB vaccine development efforts. As no major regulatory, manufacturing or clinical impediments were identified, members of the workshop emphasized the need for greater support to further explore the potential for this delivery methodology, either alone or as an adjunct to traditional parenteral methods of vaccine administration.

Original languageEnglish (US)
Pages (from-to)3038-3046
Number of pages9
JournalVaccine
Volume33
Issue number26
DOIs
StatePublished - Jun 12 2015
Externally publishedYes

Fingerprint

National Institute of Allergy and Infectious Diseases (U.S.)
Mycobacterium tuberculosis
aerosols
Aerosols
hypersensitivity
infectious diseases
Vaccines
tuberculosis
vaccines
Education
Tuberculosis Vaccines
Tuberculosis
vaccine development
Measles Vaccine
Mycobacterium Infections
immunotherapy
infection
Immunotherapy
manufacturing
pathogenesis

Keywords

  • Aerosol vaccine
  • BCG
  • Dry powder vaccine
  • Measles vaccine
  • Mucosal immunity
  • Mucosal vaccine
  • Mycobacterium tuberculosis
  • Tuberculosis vaccine
  • Vaccine regulation

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Developing aerosol vaccines for Mycobacterium tuberculosis : Workshop proceedings. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014. / Aerosol Vaccines for Tuberculosis Workshop Summary Group.

In: Vaccine, Vol. 33, No. 26, 12.06.2015, p. 3038-3046.

Research output: Contribution to journalArticle

@article{ea6ba3a0d7a9490a975753ab31f07159,
title = "Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.",
abstract = "On April 9, 2014, Aeras and the National Institute of Allergy and Infectious Diseases convened a workshop entitled {"}Developing Aerosol Vaccines for Mycobacterium tuberculosis{"} in Bethesda, MD. The purpose of the meeting was to explore the potential for developing aerosol vaccines capable of preventing infection with M. tuberculosis (Mtb), preventing the development of active tuberculosis (TB) among those latently infected with Mtb, or as immunotherapy for persons with active TB. The workshop was organized around four key questions relevant to developing and assessing aerosol TB vaccines: (1) What is the current knowledge about lung immune responses and early pathogenesis resulting after Mtb infection and what are the implications for aerosol TB vaccine strategies? (2) What are the technical issues surrounding aerosol vaccine delivery? (3) What is the current experience in aerosol TB vaccine development? and (4) What are the regulatory implications of developing aerosol vaccines, including those for TB? Lessons learned from the WHO effort to develop an aerosol measles vaccine served as a case example for overall discussions at the meeting. Workshop participants agreed that aerosol delivery represents a potentially important strategy in advancing TB vaccine development efforts. As no major regulatory, manufacturing or clinical impediments were identified, members of the workshop emphasized the need for greater support to further explore the potential for this delivery methodology, either alone or as an adjunct to traditional parenteral methods of vaccine administration.",
keywords = "Aerosol vaccine, BCG, Dry powder vaccine, Measles vaccine, Mucosal immunity, Mucosal vaccine, Mycobacterium tuberculosis, Tuberculosis vaccine, Vaccine regulation",
author = "{Aerosol Vaccines for Tuberculosis Workshop Summary Group} and Achkar, {Jacqueline M.} and Peter Beverley and Henry Boom and Tom Evans and Willem Hanekom and Anthony Hickey and Daniel Hoft and Deepika Lakhani and Lin, {Philana Ling} and Roshan Ramanathan and Henao-Restrepo, {Ana Maria} and Chad Roy and Larry Schlesinger and Robert Seder and Richard Silver and Christine Sizemore and Sally Sharpe and Eric Tsao and Zhou Xing and Lewis Schrager",
year = "2015",
month = "6",
day = "12",
doi = "10.1016/j.vaccine.2015.03.060",
language = "English (US)",
volume = "33",
pages = "3038--3046",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",

}

TY - JOUR

T1 - Developing aerosol vaccines for Mycobacterium tuberculosis

T2 - Workshop proceedings. National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, April 9, 2014.

AU - Aerosol Vaccines for Tuberculosis Workshop Summary Group

AU - Achkar, Jacqueline M.

AU - Beverley, Peter

AU - Boom, Henry

AU - Evans, Tom

AU - Hanekom, Willem

AU - Hickey, Anthony

AU - Hoft, Daniel

AU - Lakhani, Deepika

AU - Lin, Philana Ling

AU - Ramanathan, Roshan

AU - Henao-Restrepo, Ana Maria

AU - Roy, Chad

AU - Schlesinger, Larry

AU - Seder, Robert

AU - Silver, Richard

AU - Sizemore, Christine

AU - Sharpe, Sally

AU - Tsao, Eric

AU - Xing, Zhou

AU - Schrager, Lewis

PY - 2015/6/12

Y1 - 2015/6/12

N2 - On April 9, 2014, Aeras and the National Institute of Allergy and Infectious Diseases convened a workshop entitled "Developing Aerosol Vaccines for Mycobacterium tuberculosis" in Bethesda, MD. The purpose of the meeting was to explore the potential for developing aerosol vaccines capable of preventing infection with M. tuberculosis (Mtb), preventing the development of active tuberculosis (TB) among those latently infected with Mtb, or as immunotherapy for persons with active TB. The workshop was organized around four key questions relevant to developing and assessing aerosol TB vaccines: (1) What is the current knowledge about lung immune responses and early pathogenesis resulting after Mtb infection and what are the implications for aerosol TB vaccine strategies? (2) What are the technical issues surrounding aerosol vaccine delivery? (3) What is the current experience in aerosol TB vaccine development? and (4) What are the regulatory implications of developing aerosol vaccines, including those for TB? Lessons learned from the WHO effort to develop an aerosol measles vaccine served as a case example for overall discussions at the meeting. Workshop participants agreed that aerosol delivery represents a potentially important strategy in advancing TB vaccine development efforts. As no major regulatory, manufacturing or clinical impediments were identified, members of the workshop emphasized the need for greater support to further explore the potential for this delivery methodology, either alone or as an adjunct to traditional parenteral methods of vaccine administration.

AB - On April 9, 2014, Aeras and the National Institute of Allergy and Infectious Diseases convened a workshop entitled "Developing Aerosol Vaccines for Mycobacterium tuberculosis" in Bethesda, MD. The purpose of the meeting was to explore the potential for developing aerosol vaccines capable of preventing infection with M. tuberculosis (Mtb), preventing the development of active tuberculosis (TB) among those latently infected with Mtb, or as immunotherapy for persons with active TB. The workshop was organized around four key questions relevant to developing and assessing aerosol TB vaccines: (1) What is the current knowledge about lung immune responses and early pathogenesis resulting after Mtb infection and what are the implications for aerosol TB vaccine strategies? (2) What are the technical issues surrounding aerosol vaccine delivery? (3) What is the current experience in aerosol TB vaccine development? and (4) What are the regulatory implications of developing aerosol vaccines, including those for TB? Lessons learned from the WHO effort to develop an aerosol measles vaccine served as a case example for overall discussions at the meeting. Workshop participants agreed that aerosol delivery represents a potentially important strategy in advancing TB vaccine development efforts. As no major regulatory, manufacturing or clinical impediments were identified, members of the workshop emphasized the need for greater support to further explore the potential for this delivery methodology, either alone or as an adjunct to traditional parenteral methods of vaccine administration.

KW - Aerosol vaccine

KW - BCG

KW - Dry powder vaccine

KW - Measles vaccine

KW - Mucosal immunity

KW - Mucosal vaccine

KW - Mycobacterium tuberculosis

KW - Tuberculosis vaccine

KW - Vaccine regulation

UR - http://www.scopus.com/inward/record.url?scp=84930542224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930542224&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.03.060

DO - 10.1016/j.vaccine.2015.03.060

M3 - Article

VL - 33

SP - 3038

EP - 3046

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -